Basic Sciencemoderate evidence
3D-generation of high-purity midbrain dopaminergic progenitors and lineage-guided refinement of grafts supports Parkinson's disease cell therapy.
Cell stem cell·November 6, 2025·PMID 41151578
Why it mattersCurrent hPSC-based therapies for Parkinson's disease suffer from low in vivo yield of desired neurons and risk of off-target cells. This work provides a scalable method to produce high-purity, lineage-defined grafts with improved safety and efficacy, directly addressing key barriers to clinical translation.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled